New Zealand Gazette – 1999 – No. 64

Page 1482

✨ Medicines Notices



1482

NEW ZEALAND GAZETTE

No. 64

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Salbutamol sulphate 120 µg/dose equivalent to 100 µg/dose salbutamol Inhaler, aerosol, metered 3M Health Care (UK) Limited, Loughborough, Leicestershire, England Airomir Autohaler
Gemcitabine hydrochloride 228 mg, 1,140 mg equivalent to 200 mg, 1 g gemcitabine free base Infusion, solution Lilly Technology Center, Indianapolis, Indiana, United States of America; and Lilly France SA., Fegersheim, France Gemzar
Clarithromycin 500 mg Tablet, modified release Abbott Laboratories (UK) Limited, Queensborough, Kent, England; Abbott Australasia Pty Limited, Kurnell, New South Wales, Australia; and Abbott SpA., Campoverde di Aprilia, Latina, Italy Klacid OD
Mometasone furoate monohydrate 50 µg/dose Spray, nasal solution Schering-Plough Laboratories NV., Heist-op-den-Berg, Belgium; and Schering-Plough Products Inc., Manati, Puerto Rico Nasonex
Mometasone furoate monohydrate 50 µg/dose Spray, nasal solution Schering-Plough Laboratories NV., Heist-op-den-Berg, Belgium; and Schering-Plough Products Inc., Manati, Puerto Rico Rhinax
Mometasone furoate monohydrate 50 µg/dose Spray, nasal solution Schering-Plough Laboratories NV., Heist-op-den-Berg, Belgium; and Schering-Plough Products Inc., Manati, Puerto Rico Uniclar

Dated this 28th day of May 1999.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go4003

Classification of Medicines

Pursuant to section 106 (1) of the Medicines Act 1981, I, G. R. Boyd, Chief Advisor, Regulation and Safety, acting under delegated authority, hereby declare the following:

  1. The medicines listed in Schedule 1 to this notice are classified as prescription medicines.
  2. The medicines listed in Schedule 2 to this notice are classified as restricted medicines.
  3. The medicines listed in Schedule 3 to this notice are classified as pharmacy-only medicines.

Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.

Unless specific reference is made otherwise, every reference applies also to medicines that are:

(a) Preparations and admixtures containing any proportion of any substance listed in the notice;
(b) Salts and esters of any substance listed in the notice;
(c) Preparations or extracts of biological materials listed in the notice;
(d) Salts or oxides of elements listed in the notice.

Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.

Schedule 1

Prescription Medicines

abacavir

alkyl sulfonals

amphotericin

androisoxazole

azelaiac acid; except for dermal use

bicalutamide

bolasterone

bolazine

boldenone (dehydrotestosterone)

bolenol

bolmantalate

butylchloral hydrate

4-chloromethandienone

calusterone

candididin

capuride

cefacetrile

cefaforidine

cefapirin

chloralformamide

chloral hydrate; except in topical preparations containing 2% or less

chloralose

chlorandrostenolone

chloroform; for use in anaesthesia; except when specified elsewhere in the Schedules

chloroxydienone

chloroxymesterone (dehydrochloromethyltestosterone)

clocortolone



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa — PDF NZ Gazette 1999, No 64


NZLII — PDF NZ Gazette 1999, No 64




✨ LLM interpretation of page content

🏥 Consent to the Distribution of Changed Medicines (continued from previous page)

🏥 Health & Social Welfare
28 May 1999
Medicines Act, Changed Medicines, Schedule
  • G. R. Boyd, Chief Advisor, Regulation and Safety

🏥 Classification of Medicines

🏥 Health & Social Welfare
Medicines Act, Prescription Medicines, Restricted Medicines, Pharmacy-only Medicines
  • G. R. Boyd, Chief Advisor, Regulation and Safety